Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2017; 06(04): 169-170
DOI: 10.4103/sajc.sajc_65_17
Original Article : Lung Cancer

Regional reporting of the incidence of Anaplastic Lymphoma Kinase mutation in 379 non-small-cell lung cancer patients from Kolkata: Using immunohistochemistry as the diagnostic modality in a significant subset

Koushik Chatterjee
Department of Radiotherapy, IPGMER and SSKM Hospitals, Kolkata, West Bengal
,
Raja Bhowmik
Department of Radiotherapy, IPGMER and SSKM Hospitals, Kolkata, West Bengal
,
Bhargab Chattopadhyay
Department of Clinical Research, DACRRI, under CCRH, Ministry of AYUSH, Govt. of , Kolkata, West Bengal
› Author Affiliations Source of Support:All ALK mutation tests were done by Pfizer Ltd., as a part of their Patients Assistance Programme.
› Further Information
  PDF Download Permissions and Reprints

Abstract

Context: Regional epidemiology of anaplastic lymphoma kinase (ALK) mutation in non-small-cell lung cancer (NSCLC) is an unmet need in India, and so is the knowledge of its incidence based on immunohistochemistry (IHC). Aims: Reporting the incidence of ALK mutation in NSCLC from Kolkata, incorporating IHC as the diagnostic modality in a considerable subset of patients. Subjects and Methods: It is a retrospective observational study done on NSCLC patients with adenocarcinoma histology, unselected , whose samples were tested for ALK mutation status between March 1, 2013, and March 15, 2017. The study involved all cancer facilities in Kolkata, except Tata Medical Centre. Up to June 2015, the tests were done by fluorescence in situ hybridization (FISH) and from July 2015 to the end, tests were done using IHC, as per the standard testing guidelines existing during the respective time periods. Results were documented in a de-identified manner to analyze the incidence of ALK mutations. Results: A total of 379 patients was tested for ALK mutations. March 2013 to June 2015, 200 (52.77%) patients were tested by FISH, 17 (8.5%) samples were unreportable and 4 patients [(2.19%) 4/183] tested positive for ALK mutations. From July 2015 to March 2017, 179 (47.22%) patients were tested by IHC, 9 (5.02%) samples were unreportable, and 10 patients [(5.88%) 10/170] tested positive for ALK mutations. Overall, 26 (6.8%) samples were unreportable and 14 [(3.9%) 14/353] patients tested positive for ALK mutations. Conclusions: The overall incidence of ALK mutation positive NSCLC in Kolkata is 3.9%. The incidence by IHC is 5.88% and by FISH is 2.19%, in the subset of patients tested by these two modalities respectively.

Key words

Anaplastic lymphoma kinase gene rearrangement - anaplastic lymphoma kinase mutation by immunohistochemistry - anaplastic lymphoma kinase mutation in lung adenocarcinoma unselected - anaplastic lymphoma kinase mutation in nonsmall cell lung cancer - incidence of anaplastic lymphoma kinase mutation from Kolkata


Publication History

Article published online:
22 December 2020

© 2017. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6.
  • 2 Desai SS, Shah AS, Prabhash K, Jambhekar NA. A year of anaplastic large cell kinase testing for lung carcinoma: Pathological and technical perspectives. Indian J Cancer 2013;50:80-6.
  • 3 Doval D, Prabhash K, Patil S, Chaturvedi H, Goswami C, Vaid A, et al. Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung. Onco Targets Ther 2015;8:117-23.
  • 4 Accessdata.fda.gov. Department of Health and Human Services, Food and Drugs Administration; Vysis ALK Break-Apart FISH Probe Kit. Silver Spring, MD. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf11/p110012a.pdf. [Last accessed on 2017 Apr 12].
  • 5 Lira ME, Kim TM, Huang D, Deng S, Koh Y, Jang B, et al. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. J Mol Diagn 2013;15:51-61.
  • 6 Accessdata.fda.gov. Department of Health and Human Services, Food and Drugs Administration; Ventana ALK Rabbit Monoclonal Antibody Assay. Silver Spring, MD. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf14/P140025b.pdf. [Last accessed on 2017 Apr 12].
  • 7 Li Y, Pan Y, Wang R, Sun Y, Hu H, Shen X, et al. ALK-rearranged lung cancer in Chinese: A comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR. PLoS One 2013;8:e69016.
  • 8 Blackhall FH, Peters S, Bubendorf L, Dafni U, Kerr KM, Hager H, et al. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape Project. J Clin Oncol 2014;32:2780-7.
  • 9 Tantraworasin A, Lertprasertsuke N, Kongkarnka S, Euathrongchit J, Wannasopha Y, Saeteng S. Retrospective study of ALK rearrangement and clinicopathological implications in completely resected non- small cell lung cancer patients in Northern Thailand: Role of screening with D5F3 antibodies. Asian Pac J Cancer Prev 2014;15:3057-63.
  • 10 Yang P, Kulig K, Boland JM, Erickson-Johnson MR, Oliveira AM, Wampfler J, et al. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol 2012;7:90-7.